Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Jul 19, 2005

166_ip_2005-07-19_dc54be17-a00e-4c08-ac5d-5b06f7d40250.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Health Care Worldwide

Goldman Sachs – 2 6th Annual Global Healthcare Conference June 13-16, 2005

Structure Fresenius Group

  • • Dialysis Products
  • • Dialysis Care
  • • Infusion Therapy

  • • Clinical Nutrition

  • •Transfusion Technol ogy

  • • Management of Hospitals
  • • Hospital Engineering and Services
  • • Pharmaceutical Engineeri ng and Servi ces
  • • Develo p m ent of Inn o v ative Drugs and Therapie s in Oncol ogy a nd Immun ology

Fresenius owns 50.8% of the ordinary shares of Fresenius Medical Care (36.9% of total capital); Fresenius Medical Care is fully consolidated in the financial statements of Fresenius AG

©

Fresenius Group: Excellent Start into 2005

Fresenius Kabi: Infusion Therapy and Clinical Nutrition for the Hospital and Outpatient Markets

  • No. 1 in infusion and nutrition therapy in Europe
  • Significant market positions in emerging markets (Asia, Latin America)
  • Disease demographics drive growing demand
  • Focus on generic I.V. drug expansion opportunities in Europe
  • Selected acquisitions to expand international business
  • Outlook 2005: Sales growth: ~ 10 % EBIT margin: > 13 %

Sales '04: 10 8 €m

Fresenius ProServe: Management and Technical Services in Health Care

  • Fresenius ProServe is one of the major private hospital operators in Germany
  • Long-standing experience in technical health care services worldwide
  • Streamlined and restructured operations in 2003/2004
  • Improved earnings outlook
  • Outlook 2005: Sales growth (organic): 5 - 8 % EBIT: 20 - 25 €m

Management of Hospitals in Germany (Wittgensteiner Kliniken)

Sales '04: 34 3 €m

Hospital Engineering + Services (VAMED)

Sales '04: 35 2 €m

Pharmaceutical Engineering + Services (Pharmaplan)

Sales '04: 79 €m

Fresenius Biotech: New Growth Opportunities

Focussed on:

  • - Antibody therapies for the treatment of cancer
  • - Cell therapies for the treatment of the immune system
  • New product launches expected in late 2007
  • Clinical study program on track
  • Phase I studies completed to evaluate trifunctional antibodies in the treatment of breast cancer and peritoneal carcinomatosis
  • Expected spending level 2005: 35 - 40 €m

Sales '04: 17 €m

Sales '04: 1 €m

Fresenius Group: 2005 Financial Outlook Confirmed*

Target

R
h
t
e
e
n
e
g
r
o
v
u
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 6
9
%
-
N
i
h
t
t
e
n
c
o
m
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 5
1
2
0
%
-
C
i
l
d
i
t
t
a
p
a
e
x
p
e
n
u
r
e		 4
0
0
4
5
0
€
m
-

* pre Fresenius Medical Care's acquisition of Renal Care Group

Fresenius

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Health Care Worldwide

Goldman Sachs – 2 6th Annual Global Healthcare Conference June 13-16, 2005

of the time of the 1001
ASSETT 11299 1804 425
1.62
RE DEPOSITION 31 JA recenter & 6 0.044
Cart and cash stavalers. 9.529 13
Trade accepts Incorners less frescreen 1 87 143
619 711
By multiful actually 6 113 1.6.3
Acasuri) resisted from restor protested parties. 1 144 2.144
STERESHOUSE LEA 211 2,154 1,727
erepaid experies and sther current autom 1,498 7,873
Defermit tases (carrents 11 2,905 0.00
Tatal current aussets HM
Tampile smart. 1 114 30
Delivell
Omer stamplike acses. 28 11/8 el
5,439 -1
Other natical/wel 28895 8.384
Daferred taxes burry current
H. Tutal non carrent assets

Attachments

Investment Considerations

  • Leading global market positions in dialysis and in infusion/nutrition therapies – active in more than 100 countries
  • Strong global presence in non-cyclical and growing markets; steady growth in sales and cash flow
  • Unique competitive advantages in technology, products and therapies
    • – Leading proprietary technologies in dialyzer membranes, dialysis machines, lipid emulsion technology, sterile packaging
    • – Cost leadership due to significant mar ket shares in dialysis and infusion/ nutrition therapies
    • – Largest global clinics and patient data network in dialysis
    • – Significant margin upsides in Fresenius Kabi, Fresenius ProServe and Fresenius Biotech business segments in addition to organic growth
  • Industry-leading management teams with more than 120 years of combined renal experience at Fresenius Medical Care and more than 115 years of combined health care experience at Fresenius Kabi

Fresenius Group: Profit and Loss Statement

i
€
n
m		 Q
1
2
0
0
5		 Q
1
2
0
0
4		 C
h
a
n
g
e
l
t
a
c
u
a
t
r
a
e
s		 C
h
a
n
g
e
t
t
c
o
n
s
a
n
t
r
a
e
s
S
l
a
e
s		 1
8
7
7
,		 1
2
0
7
,		 4
%
+		 6
%
+		 4
%
i
h
t
o
r
g
a
n
c
g
r
o
w
E
B
I
T		 2
1
2		 1
9
7		 8
%
+		 1
0
%
+		 i
i
1
1
9
%
t
m
a
r
g
n
n
c
r
e
a
s
e
o
I
l
t
t
t
n
e
r
e
s
r
e
s
u		 4
7
-		 5
2
-		 1
0
%
+		 8
%
+		 l
d
b
l
l
t
o
w
e
r
a
v
e
r
a
g
e
e
e
v
e
s
d
i
t
t
t
a
n
n
e
r
e
s
r
a
e
s
T
a
x
e
s		 6
5
-		 8
5
-		 1
2
%
-		 1
4
%
-		 i
h
i
f
l
l-
i
t
t
t
w
n
u
y
e
a
r
e
x
p
e
c
a
o
n
f
3
9
4
0
%
o
-
N
i
t
e
n
c
o
m
e		 4
6		 3
9		 1
8
%
+		 2
1
%
+		 i
l
d
f
i
i
l
t
o
p
e
r
a
o
n
a
a
n
n
a
n
c
a
i
t
m
p
r
o
v
e
m
e
n
s
S
(
)
(
)
E
P
f
€
p
r
e
s		 1
1
2		 0
9
5		 1
8
%
+		 2
1
%
+

Fresenius Group: Cash Flow

i
€
n
m		 Q
1
2
0
0
5		 Q
1
2
0
0
4		 C
h
a
n
g
e
C
f
h
l
a
s
o
w		 1
7
6		 1
6
5		 %
7		 9
8
%
i
m
a
r
g
n
C
h
i
W
k
i
i
t
a
n
g
e
n
o
r
n
g
c
a
p		 l
8
a
-		 1
7		 i
f
l
d
b
F
M
E
t
n
e
n
c
e
a
u
y
x
i
N
A
t
p
a
y
m
e
n
n
O
C
f
i
h
l
t
p
e
r
a
n
g
a
s
o
w		 1
6
8		 1
8
2		 8
%
-
C
(
)
t
a
p
e
n
e
x		 4
2
-		 4
6
-		 9
%
-		 i
l
l
i
Q
1
t
t
t
y
p
c
a
s
o
w
s
a
r
n
C
F
h
f
l
r
e
e
a
s
o
w
(
b
f
i
i
i
d
d
i
i
d
d
)
t
e
o
r
e
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 1
2
6		 1
3
6		 7
%
-
A
i
i
i
(
)
t
t
c
q
s
o
n
s
n
e
u		 5
1
3
-		 3
7
-		 i
l
F
i
K
b
i
m
a
n
r
e
s
e
n
s
a
y
u
D
i
i
d
d
v
e
n
s		 0 1
-
C
f
F
h
l
r
e
e
a
s
o
w
(
f
)
i
i
i
d
d
i
i
d
d
t
t
a
e
r
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 9
-		 9
8

Fresenius Group: Solid Balance Sheet Structure

Fresenius Group: Debt and Interest Ratios

Q
1
2
0
0
5		 Q
4
2
0
0
4
D
b
t
e
(
€
)
m		 2
8
1
3
,		 2
7
3
5
,
N
d
b
t
t
(
)
e
e
€
m		 2
6
6
7
,		 2
5
9
5
,
/
N
d
b
E
B
I
T
D
A
t
t
e
e		 2
3		 2
2
/
E
B
I
T
D
A
I
t
t
n
e
r
e
s		 6
0		 5
6

Business Segments: Key Highlights Q1 2005

F
i
r
e
s
e
n
s
u
C
M
d
i
l
e
c
a
a
r
e		 F
i
r
e
s
e
n
s
u
K
b
i
a		 F
i
r
e
s
e
n
u
s
S
P
r
o
e
r
v
e
\$
i
i
U
S
t
r
e
p
o
r
n
g
n		 i
i
€
t
r
e
p
o
r
n
g
n		 i
i
€
t
r
e
p
o
r
n
g
n
S
l
a
e
s
G
h
t
r
o
w		 \$
S
1
6
0
9
U
m
,
1
0
%
+		 3
9
8
€
m
1
0
%
+		 €
1
1
7
m
1
4
%
-
E
B
I
T
G
h
t
r
o
w		 \$
S
2
2
0
U
m
1
1
%
+		 2
€
5
m
2
%
7
+		 3
€
m
2
0
0
%
+
  • Fresenius Medical Care
    • Excellent net income growth of 18 %
    • Strong performance in US and Europe continued

  • Fresenius Kabi

  • Fresenius ProServe
    • Substantial increase in operating margin
    • Improved sales perfor mance in Ger man market
    • Earnings improvement accomplished
    • Project delays at VAME D

Fresenius Kabi: Sales Growth in All Regions

  • German sales: back on growth path
  • European sales: strong increase due to Labesfal and Infusia acquisitions
  • Asia-Pacific sales: continued double-digit growth

Fresenius Kabi: Excellent EBIT Performance

€
m		 Q
1
2
0
0
5		 Q
1
2
0
0
4		 C
h
a
n
g
e
E
B
I
T
E
B
I
T
i
m
a
r
g
n		 5
2
1
3
1
%		 4
1
1
1
3
%		 2
7
%
+
i
E
B
I
T
b
R
e
g
o
n
y
:
E
u
r
o
p
e
E
B
I
T
i
m
a
r
g
n		 5
0
1
6
7
%		 4
1
1
4
9
%		 2
2
%
+
I
i
l
t
t
n
e
r
n
a
o
n
a
E
B
I
T
i
m
a
r
g
n		 1
6
1
6
3
%		 1
2
1
4
0
%		 3
3
%
+
C
/
C
R
&
D
t
t
o
r
p
o
r
a
e
o
r
p
o
r
a
e		 1
4
-		 1
2
-		 1
7
%
-

Fresenius ProServe: Key Figures Q1 2005

€
m		 Q
5
1
2
0
0		 Q
1
2
0
0
4		 C
h
a
n
g
e
S
l
a
e
s		 1
7
1		 1
9
9		 *
1
4
%
-
H
i
l
M
t
t
o
s
p
a
a
n
a
g
e
m
e
n
(
)
W
K
A
-		 8
5		 8
4		 2
%
+
H
i
l
E
i
i
S
i
t
(
)
o
s
p
a
n
g
n
e
e
r
n
g
+
e
r
v
c
e
s
V
A
M
E
D
-		 7
2		 8
6		 1
6
%
-
S
P
h
i
l
E
i
i
i
t
a
r
m
a
c
e
u
c
a
n
g
n
e
e
r
n
g
+
e
r
v
c
e
s
-
(
)
P
h
l
a
r
m
a
p
a
n		 1
3		 2
0		 3
%
5
-
O
h
**
t
e
r
s
(
l
d
/
l
d
i
2
0
0
4
)
s
o
c
o
s
e
n
-		 0 9
E
B
I
T		 3 1 -

* -10 % organic; **hospitalia care; hospitalia activHealth

Financial Calender

A
4
2
0
0
5
t
g
s
u
u
,		 t
f
R
1
h
l
2
0
0
5
t
s
e
p
o
r
o
n
a
N
b
3
2
0
0
5
o
v
e
m
e
r
,		 d
t
R
1
3
2
0
0
5
t
t
s
r
e
p
o
r
o
n
q
u
a
r
e
r
s
–

Contact

Birgit Grund SVP Investor Relations Fresenius AG

Telephone: e-mail:

++49 6172 608-2485 [email protected]

Further information and current news: http://www.fresenius-ag.com

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.